Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients | Zendy

Naohiko Nakamura | Zendy; Daisuke Kaida | Zendy; Yasuto Tomita | Zendy; Takashi Miyata | Zendy; Tomoharu Miyashita | Zendy; Hideto Fujita | Zendy; Shinichi Kinami | Zendy; Nobuhiko Ueda | Zendy; Hiroyuki Takamura | Zendy

Open Access

Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients

Author(s) -

Naohiko Nakamura,

Daisuke Kaida,

Yasuto Tomita,

Takashi Miyata,

Tomoharu Miyashita,

Hideto Fujita,

Shinichi Kinami,

Nobuhiko Ueda,

Hiroyuki Takamura

Publication year - 2022

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10107

Subject(s) - trastuzumab , medicine , chemotherapy , immunohistochemistry , univariate analysis , gastrectomy , cancer , oncology , fibroblast growth factor receptor 2 , gastroenterology , multivariate analysis , fibroblast growth factor , receptor , breast cancer

This study aimed to evaluate the relationship between clinical outcomes and intra-tumoral fibroblast growth factor receptor 2 (FGFR2) expression in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) patients who had undergone HER2-targeted chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research